vs
Side-by-side financial comparison of Syndax Pharmaceuticals Inc (SNDX) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
Viridian Therapeutics, Inc.\DE is the larger business by last-quarter revenue ($70.6M vs $68.5M, roughly 1.0× Syndax Pharmaceuticals Inc). Viridian Therapeutics, Inc.\DE runs the higher net margin — -49.0% vs -99.3%, a 50.3% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 791.7%).
Syndax Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing innovative oncology therapies for patients with hard-to-treat cancers. Its pipeline includes targeted and immunotherapy candidates addressing unmet medical needs, primarily serving global oncology healthcare stakeholders and patient populations.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
SNDX vs VRDN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $68.5M | $70.6M |
| Net Profit | $-68.0M | $-34.6M |
| Gross Margin | — | — |
| Operating Margin | -91.3% | -56.7% |
| Net Margin | -99.3% | -49.0% |
| Revenue YoY | 791.7% | 81958.1% |
| Net Profit YoY | 27.8% | 54.9% |
| EPS (diluted) | $-0.78 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $68.5M | — | ||
| Q3 25 | $45.9M | $70.6M | ||
| Q2 25 | $38.0M | — | ||
| Q1 25 | $20.0M | — | ||
| Q3 24 | $12.5M | — | ||
| Q1 24 | $0 | — | ||
| Q3 23 | $0 | — | ||
| Q2 23 | $0 | — |
| Q4 25 | $-68.0M | — | ||
| Q3 25 | $-60.7M | $-34.6M | ||
| Q2 25 | $-71.8M | — | ||
| Q1 25 | $-84.8M | — | ||
| Q3 24 | $-84.1M | — | ||
| Q1 24 | $-72.4M | — | ||
| Q3 23 | $-51.1M | — | ||
| Q2 23 | $-44.6M | — |
| Q4 25 | -91.3% | — | ||
| Q3 25 | -125.2% | -56.7% | ||
| Q2 25 | -182.7% | — | ||
| Q1 25 | -417.9% | — | ||
| Q3 24 | -716.6% | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | -99.3% | — | ||
| Q3 25 | -132.4% | -49.0% | ||
| Q2 25 | -189.3% | — | ||
| Q1 25 | -423.3% | — | ||
| Q3 24 | -673.0% | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | $-0.78 | — | ||
| Q3 25 | $-0.70 | — | ||
| Q2 25 | $-0.83 | — | ||
| Q1 25 | $-0.98 | — | ||
| Q3 24 | $-0.98 | — | ||
| Q1 24 | $-0.85 | — | ||
| Q3 23 | $-0.73 | — | ||
| Q2 23 | $-0.64 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $394.1M | $490.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $64.6M | $503.0M |
| Total Assets | $529.7M | $577.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $394.1M | — | ||
| Q3 25 | $436.0M | $490.9M | ||
| Q2 25 | $455.2M | — | ||
| Q1 25 | $512.2M | — | ||
| Q3 24 | $389.6M | — | ||
| Q1 24 | $434.6M | — | ||
| Q3 23 | $363.6M | — | ||
| Q2 23 | $398.8M | — |
| Q4 25 | $64.6M | — | ||
| Q3 25 | $115.4M | $503.0M | ||
| Q2 25 | $157.4M | — | ||
| Q1 25 | $215.1M | — | ||
| Q3 24 | $366.4M | — | ||
| Q1 24 | $491.9M | — | ||
| Q3 23 | $359.2M | — | ||
| Q2 23 | $400.0M | — |
| Q4 25 | $529.7M | — | ||
| Q3 25 | $551.8M | $577.1M | ||
| Q2 25 | $596.1M | — | ||
| Q1 25 | $640.7M | — | ||
| Q3 24 | $425.8M | — | ||
| Q1 24 | $543.0M | — | ||
| Q3 23 | $399.2M | — | ||
| Q2 23 | $431.3M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-69.5M | $-84.6M |
| Free Cash FlowOCF − Capex | — | $-84.7M |
| FCF MarginFCF / Revenue | — | -120.1% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-69.5M | — | ||
| Q3 25 | $-70.5M | $-84.6M | ||
| Q2 25 | $-87.8M | — | ||
| Q1 25 | $-95.2M | — | ||
| Q3 24 | $-62.3M | — | ||
| Q1 24 | $-83.5M | — | ||
| Q3 23 | $-44.7M | — | ||
| Q2 23 | $-35.4M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $-84.7M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -120.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
